. 2016 Sep 30;7(44):72184–72196. doi: 10.18632/oncotarget.12360

Table 4. Significant Spearman rank-correlations with R-values > 0.20 between intratumoral and stromal CD66b⁺ TANs and tumor-associated markers in samples from NSCLC in the total cohort and in subgroups according to histology (Total cohort = 326, SCC = 191; ADC = 95).

	ALL		SCC		ADC
	Correlations with markers expressed in intratumoral cells
	Tumor	Stroma	Tumor	Stroma	Tumor	Stroma
CAIX						0.23^*	ANG	T
CD34					−0.27^**	−0.27^**	ANG	T
D240					0.21^*		ANG	T
DLL4	−0.20^***					−0.24^*	ANG	T
FGFR1					−0.23^*		ANG	T
Glut1					0.28^**		ANG	T
NOTCH1					0.25^*		ANG	T
NOTCH4			−0.22^**				ANG	T
PHD-3						−0.33^***	ANG	T
Bad-cyt			−0.24^***		−0.21^*	−0.22^*	EMT	T
Bad-Nuc			−0.24^**				EMT	T
Her3			−0.21^**				EMT	T
Ki67					0.22^*		EMT	T
pHer2				−0.22^**			EMT	T
pi3K			−0.21^***				EMT	T
CD66b		0.76^#		0.80^#		0.66^#	IMM	T
CD68	0.23^#		0.28^***	0.28^#			IMM	T
MCT1						0.22^*	MET	T
MCT4		0.22^#	0.22^**	0.27^#			MET	T
PGC1-α						−0.23^*	MET	T
	Correlations with markers expressed in tumor stroma
	Tumor	Stroma	Tumor	Stroma	Tumor	Stroma
Ang2					0.21^*		ANG	S
D240					0.24^*		ANG	S
DLL4				0.21^**			ANG	S
miR21		0.21^***				0.23^*	ANG	S
NOTCH4				0.21^**			ANG	S
PDGF-A			0.22^**	0.23^**	0.23^*		ANG	S
VEGF-A			0.22^**				ANG	S
VEGF-D				0.21^**	0.21^*		ANG	S
cAkt				0.24^***			EMT	S
ERK3				0.20^**			EMT	S
IGF1				0.21^**			EMT	S
NfκB				0.23^**			EMT	S
PAR6			0.22^**				EMT	S
CD138				0.21^**			IMM	S
CD1a			0.20^**				IMM	S
CD66b	0.76^#		0.80^#		0.66^#		IMM	S
CSF1R	0.23^#	0.25^#	0.26^***	0.28^#	0.23^*	0.21^*	IMM	S
CXCL16				0.25^***			IMM	S
FOXP3				0.21^**			IMM	S
CD68		0.23^#	0.23^**	0.27^#			IMM	S
MCSF	0.28^#	0.25^#	0.32^#	0.32^#			IMM	S
FOXO1A				0.28^#			IMM	S
LDH5				0.24^***			MET	S
MCT1	0.23^#	0.26^#	0.23^**	0.30^#	0.28^**	0.24^*	MET	S
MCT4	0.22^#	0.20^***	0.20^**		0.23^*	0.27^**	MET	S

Abbreviations: CD, cluster of differentiation; SCC, squamous cell carcinoma; ADC, adenocarcinoma;ANG, angiogenesis; EMT, epithelial-mesenchymal transition; MET, metastasis; IMM; immunology; CAIX, Anti-Carbonic Anhydrase IX;DLL4, Delta ligand 4; FGFR1, Fibroblast Growth Factor Receptor 1; GLUT1, Glucose transporter 1; PHD, prolyl hydroxylase-domain; BAD, Bcl2 Associated Death Promoter; Cyt, in cytoplasm; Nuc, in nucleus; Her, human epidermal growth factor receptor; MCT, monocarboxylate transporter; PGC1, Peroxisome proliferative activated receptor gamma coactivator 1; Ang, angiogenin; miR, micro RNA; PDGF, Platelet-derived growth factor; VEGF, Vascular endothelial growth factor; IGF1, Insulin like growth factor 1; PAR6, Partitioning defective 6; CXCL16, C-X-C motif ligand; FOX, forkhead box; MCSF, Macrophage Colony Stimulating Factor 1; CSF1R, Colony stimulating factor 1 receptor; LDH, lactate dehydrogenase.

significant at p > 0.05,

^**

significant at p > 0.01,

^***

significant at p >0.001,

significant after Bonferroni correction for multiple tests

Table 4. Significant Spearman rank-correlations with R-values > 0.20 between intratumoral and stromal CD66b+ TANs and tumor-associated markers in samples from NSCLC in the total cohort and in subgroups according to histology (Total cohort = 326, SCC = 191; ADC = 95).

Table 4. Significant Spearman rank-correlations with R-values > 0.20 between intratumoral and stromal CD66b⁺ TANs and tumor-associated markers in samples from NSCLC in the total cohort and in subgroups according to histology (Total cohort = 326, SCC = 191; ADC = 95).